The UK’s New Approach to Market Access: Innovative Licensing and Access Pathway

Brexit signaled a major shift in medicine regulation in the UK, with the Medicines and Healthcare Products Regulatory Agency (MHRA) taking the reins. In a recent Xcenda article, Farah Baig explains what this and the new Innovative Licensing and Access Pathway (ILAP) means for the industry. The ILAP stands to benefit pharma and patients by accelerating access to therapeutics. In addition, it will foster increased collaboration between regulatory agencies and industry.

According to Baig, “In addition to the 4 main bodies (MHRA, NICE, SMC, AWTTC), supporting organisations such as NHS England and NHS Improvement (NHSEI) and the National Institute for Health Research (NIHR) are associated partners within the pathway. The ILAP has notably for the first time facilitated collaboration between NICE, the AWTTC, and the SMC under a unified umbrella to support activities, provide scientific advice, and engage a variety of stakeholders in the health technology assessment (HTA) evaluation of new technologies.”

Click here to read more.

(Source: Xcenda, February 17^th, 2022)